Torii Pharmaceutical Co., Ltd. (TRXPF) Research

Torii Pharmaceutical Co., Ltd., a Tokyo-based Japanese firm established in 1872, specializes in the development and commercialization of a variety of pharmaceutical products. Its therapeutic portfolio features Riona, a medication addressing hyperphosphatemia, and REMITCH, an oral treatment for pruritus commonly experienced by patients undergoing dialysis or suffering from liver diseases. The company also produces ANTEBATE, a topical solution for skin ailments such as atopic and contact dermatitis, which functions by reducing inflammation. Furthermore, Torii Pharmaceutical provides allergen immunotherapy tablets, specifically CEDARCURE and MITICURE, in addition to CORECTIM, a topical janus kinase (JAK) inhibitor. The company's products are primarily promoted to healthcare professionals through its team of medical representatives. Originally named Torii Shoten K.K., the organization officially became Torii Pharmaceutical Co., Ltd. in May 1949, and it operates today as a subsidiary of Japan Tobacco Inc.

Market snapshot

Symbol
TRXPF
Price
$24.57
Day change
0.00%
Market cap
$178.5B
P/E ratio
43.49x
52-week range
24.57-47295476
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • AB Science S.A. (ABSCF)
  • Allergy Therapeutics plc (AGYTF)
  • Boiron S.A. (BOIRF)
  • Basilea Pharmaceutica AG (BPMUF)
  • Elite Pharmaceuticals, Inc. (ELTP)
  • Avisa Diagnostics Inc. (FOGCF)
  • ManifestSeven Holdings Corporation (MNFSF)
  • Swedencare AB (publ) (SWDCF)

Open Torii Pharmaceutical Co., Ltd. (TRXPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.